
Epic Bio, a biotechnology firm specializing in gene expression modulation through non-cutting dCas proteins, has secured Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for EPI-321 in treating facioscapulohumeral muscular dystrophy (FSHD), the most prevalent adult muscular dystrophy. EPI-321, designed to suppress abnormal DUX4 gene expression, will undergo a Phase 1/2 clinical study starting H1 2024 to assess safety and efficacy in FSHD patients. The FDA's designation provides financial benefits, including tax credits, fee waivers, and potential market exclusivity for 7 years upon approval. FSHD, affecting 4.6 in 100,000 globally, lacks a cure, and EPI-321 aims to address its molecular mechanisms through epigenetic therapy.
Like
Save
Share